BRPI0814252B8 - composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia - Google Patents

composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia

Info

Publication number
BRPI0814252B8
BRPI0814252B8 BRPI0814252A BRPI0814252A BRPI0814252B8 BR PI0814252 B8 BRPI0814252 B8 BR PI0814252B8 BR PI0814252 A BRPI0814252 A BR PI0814252A BR PI0814252 A BRPI0814252 A BR PI0814252A BR PI0814252 B8 BRPI0814252 B8 BR PI0814252B8
Authority
BR
Brazil
Prior art keywords
natalizumab
pharmaceutical composition
unit dose
filled syringe
aqueous pharmaceutical
Prior art date
Application number
BRPI0814252A
Other languages
English (en)
Inventor
Maloney Kevin
Original Assignee
Biogen Idec Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Ma Inc filed Critical Biogen Idec Inc
Publication of BRPI0814252A2 publication Critical patent/BRPI0814252A2/pt
Publication of BRPI0814252A8 publication Critical patent/BRPI0814252A8/pt
Publication of BRPI0814252B1 publication Critical patent/BRPI0814252B1/pt
Publication of BRPI0814252B8 publication Critical patent/BRPI0814252B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)

Abstract

composição farmacêutica aquosa compreendendo natalizumab a presente invenção refere-se às formulações do anticorpo de ligação vla-4.
BRPI0814252A 2007-06-14 2008-06-13 composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia BRPI0814252B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94407607P 2007-06-14 2007-06-14
PCT/US2008/066928 WO2008157356A2 (en) 2007-06-14 2008-06-13 Antibody formulations

Publications (4)

Publication Number Publication Date
BRPI0814252A2 BRPI0814252A2 (pt) 2015-04-14
BRPI0814252A8 BRPI0814252A8 (pt) 2019-01-29
BRPI0814252B1 BRPI0814252B1 (pt) 2019-12-10
BRPI0814252B8 true BRPI0814252B8 (pt) 2021-05-25

Family

ID=39956053

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814252A BRPI0814252B8 (pt) 2007-06-14 2008-06-13 composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia

Country Status (24)

Country Link
US (3) US20080311119A1 (pt)
EP (2) EP2170390B1 (pt)
JP (2) JP2010529999A (pt)
CN (2) CN103977404A (pt)
AR (2) AR067011A1 (pt)
AU (1) AU2008266051B2 (pt)
BR (1) BRPI0814252B8 (pt)
CA (1) CA2690382A1 (pt)
CY (1) CY1121208T1 (pt)
DK (1) DK2170390T3 (pt)
EA (1) EA020456B1 (pt)
ES (1) ES2707815T3 (pt)
HR (1) HRP20182146T1 (pt)
HU (1) HUE041555T2 (pt)
IL (1) IL202648B (pt)
LT (1) LT2170390T (pt)
MX (2) MX2009013593A (pt)
NZ (2) NZ595526A (pt)
PL (1) PL2170390T3 (pt)
PT (1) PT2170390T (pt)
SI (1) SI2170390T1 (pt)
TR (1) TR201820837T4 (pt)
TW (1) TWI614028B (pt)
WO (1) WO2008157356A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
JP2012533548A (ja) * 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
PL3202789T3 (pl) 2010-04-16 2020-09-21 Biogen Ma Inc. Przeciwciała anty-vla-4
CN102905692B (zh) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
WO2013006461A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
HUE045624T2 (hu) 2011-10-18 2020-01-28 Coherus Biosciences Inc Magnézium ionokkal stabilizált etanercept készítmények
CN104271122A (zh) * 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
EP2864356A1 (en) * 2012-06-21 2015-04-29 UCB Pharma, S.A. Pharmaceutical formulation
PE20150762A1 (es) 2012-07-09 2015-06-20 Coherus Biosciences Inc Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP2015533797A (ja) 2012-09-11 2015-11-26 コヒラス・バイオサイエンシズ・インコーポレイテッド 高純度および優れた収率の正確に折り畳まれたエタネルセプト
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
US20160250329A1 (en) * 2013-10-29 2016-09-01 Albumedix A/S Antibody composition
CA2924448C (en) * 2013-11-29 2021-12-14 Genentech, Inc. Antibody selection apparatus and methods
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
WO2015136468A1 (en) * 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
JP2017520531A (ja) * 2014-06-02 2017-07-27 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｆｃ断片の産生
MX2017004975A (es) * 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2021007504A2 (en) * 2019-07-10 2021-01-14 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising reduced level of host cell proteins
TW202227483A (zh) * 2020-10-30 2022-07-16 日商衛材R&D企管股份有限公司 醫藥組合物
CA3198318A1 (en) 2020-11-14 2022-05-19 Yuan Zhao Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
AU2022259605A1 (en) 2021-04-13 2023-11-02 Biogen Ma Inc. Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS62196921A (ja) 1986-02-25 1987-08-31 Nec Corp 位相検出回路
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
HU220137B (hu) 1993-01-06 2001-11-28 Kinerton Ltd. Biológiailag lebontható poliészterek és biológiailag aktív polipeptidek ionos molekuláris konjugátumai, eljárás ezek előállítására és eljárás mikrorészecskék előállítására
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK1759709T3 (da) * 1994-01-25 2013-06-10 Elan Pharm Inc Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
BRPI9715219B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
WO2008021954A2 (en) 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Method for distribution of a drug

Also Published As

Publication number Publication date
JP2010529999A (ja) 2010-09-02
TWI614028B (zh) 2018-02-11
IL202648A0 (en) 2011-08-01
LT2170390T (lt) 2019-01-10
EA201070015A1 (ru) 2010-06-30
PT2170390T (pt) 2019-02-12
BRPI0814252B1 (pt) 2019-12-10
TR201820837T4 (tr) 2019-01-21
BRPI0814252A8 (pt) 2019-01-29
ES2707815T3 (es) 2019-04-05
EP3461500A1 (en) 2019-04-03
IL202648B (en) 2018-04-30
US9533044B2 (en) 2017-01-03
US20130017193A1 (en) 2013-01-17
HRP20182146T1 (hr) 2019-02-08
AR067011A1 (es) 2009-09-30
WO2008157356A3 (en) 2009-02-19
PL2170390T3 (pl) 2019-05-31
WO2008157356A2 (en) 2008-12-24
HUE041555T2 (hu) 2019-05-28
US20120134989A1 (en) 2012-05-31
CA2690382A1 (en) 2008-12-24
MX2020005214A (es) 2020-08-20
EP2170390A2 (en) 2010-04-07
AU2008266051A2 (en) 2010-02-25
CN103977404A (zh) 2014-08-13
SI2170390T1 (sl) 2019-02-28
EP2170390B1 (en) 2018-11-07
TW200908995A (en) 2009-03-01
MX2009013593A (es) 2010-01-20
AR117403A2 (es) 2021-08-04
NZ595526A (en) 2013-03-28
EA020456B1 (ru) 2014-11-28
US20080311119A1 (en) 2008-12-18
DK2170390T3 (en) 2019-01-21
CN101778640A (zh) 2010-07-14
BRPI0814252A2 (pt) 2015-04-14
NZ582436A (en) 2012-06-29
JP2014040424A (ja) 2014-03-06
CY1121208T1 (el) 2020-05-29
AU2008266051B2 (en) 2014-07-31
AU2008266051A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
MX2012002654A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
UY30992A1 (es) Derivados de arilisoxazolina insecticidas
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
BR112013016770A2 (pt) formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica
BR112015000329A2 (pt) formulações de diclofenac
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
CR11406A (es) Conjugados de neurturina novedosos para uso farmaceutico
BRPI0918629B8 (pt) sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
MX2011007940A (es) Conjugados de oligomero-fenotiazina.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25I Requirement for requested change of headquarter

Owner name: BIOGEN MA INC. (US)

B25G Requested change of headquarter approved

Owner name: BIOGEN MA INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF